Condition

High-risk Prostate Cancer

ClinicalTrials.gov condition label

Explore related research

Search across original and mapped records

Search results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 14 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials14
Recruiting7
Common interventions25
Lead sponsors shown13
Advertisement

Clinical trials

14 shown
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate CancerNCT07027124 · 2026-05-21
RECRUITING
A Platform Study of Epigenetic Therapy Before Prostatectomy in Men With Prostate CancerNCT06888102 · 2026-04-01
RECRUITING
Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617NCT07054346 · 2025-07-08
RECRUITING
Delayed Pelvic Imaging With [68]Ga-PSMA PET/CT in a Patient With High-risk Prostate Cancer.NCT07357259 · 2025-02-03
RECRUITING
FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate CancerNCT06636682 · 2024-10-14
RECRUITING
Serial PSMA PET for Therapy Monitoring in Clinically Significant Prostate CancerNCT07553780 · 2021-03-07
RECRUITING
Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & SurgeryNCT03541928 · 2018-08-02
RECRUITING
COMBINED PSMA-PET/CT AND MRI STAGING IN INTERMEDIATE AND HIGH-RISK PATIENTS PROSTATA-CANCER (COMBINE-P)NCT07455097 · 2026-01-01
ACTIVE_NOT_RECRUITING
Immunotherapy Before and After SurgeryNCT06765902 · 2025-12-15
WITHDRAWN
Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.NCT06765954 · 2025-12-01
WITHDRAWN
Contribution of Canine Detection in the Diagnostic Strategy of High-risk Prostate Cancer (Prostate-K9-Detect)NCT05558735 · 2022-11-02
COMPLETED
Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST TrialNCT05223582 · 2021-05-01
UNKNOWN
Ga-68-PSMA-11 in High-risk Prostate CancerNCT03362359 · 2017-10-09
COMPLETED
Conventional Versus Hypofractionated Radiation in High Risk Prostate PatientsNCT01488968 · 2012-03-01
TERMINATED

Common interventions

Trial status mix

RECRUITING7
COMPLETED2
WITHDRAWN2
ACTIVE_NOT_RECRUITING1
TERMINATED1
UNKNOWN1

Phase mix

PHASE27
NA2
PHASE12
EARLY_PHASE11
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.